期刊文献+

多西他塞联合顺铂治疗上皮性卵巢癌疗效观察

原文传递
导出
摘要 目的探讨多西他塞(TXT)联合顺铂(DDP)治疗上皮性卵巢癌的疗效和毒副作用。方法48例上皮性卵巢癌经肿瘤细胞减灭术,术后给予多西他塞联合顺铂化疗(即化疗第1dTXT70~75m/m^2静脉滴注;第1~3dDDP70~75mg/m^2静脉滴注。21d为1个周期),2~3个周期后评价疗效和毒副作用。结果48例中完全缓解6例,部分缓解22例,稳定16例,进展4例,总有效率58.3%(28/48)。Ⅲ~Ⅳ度白细胞减少33.3%(16/48);Ⅲ~Ⅳ度血小板减少2.1%(1/48);Ⅲ~Ⅳ度血红蛋白减少4.2%(2/48)。脱发发生率95.8%(46/48)。结论TXT联合DDP治疗上皮性卵巢癌疗效较好,化疗毒副反应小,值得临床推广。
出处 《医学新知》 CAS 2012年第2期141-142,共2页 New Medicine
  • 相关文献

参考文献5

  • 1Siddiqui N, Boddy A V,Thomas H D, et al. A clinical and pharmacokinetic study of the combination of carboplatin and pacllitaxel for epithelial ovarian cancer. Br J Cancer, 1997,75 (2) :287-292.
  • 2李斌,刘丽影,章文华.泰索帝治疗晚期复发性卵巢癌研究现状[J].肿瘤防治杂志,2000,7(1):80-82. 被引量:8
  • 3路虹,王建东,孔为民.多西他赛作为一线用药治疗卵巢癌研究进展[J].肿瘤防治杂志,2005,12(15):1194-1196. 被引量:21
  • 4Vasey P A, Jayson G C, Gordon A, et al. Phase m randomized trial of docetaxel- carboplatin versus paclitaxel -earboplatin as first line chemotherapy for ovarian carcinoma[ J]. J Natl Cancer Inst ,2004,96 (22) :1682-1691.
  • 5Sandercock J, Parmar M K, Torri V, et al. First - line treatment for advanced ovarian cancer : paclitaxe|, platinum and the evidence [ J ]. Br J Cancer,2002,87(8) :815-824.

二级参考文献38

  • 1Piccart M J, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer[J]. J Natl Cancer Inst, 1995, 87(9):676-681.
  • 2Markman M, Kennedy A, Webster K, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum[J]. J Clin Oncol,2001, 19(7):1901-1905.
  • 3Verschraegen C F, Sittisomwong T, Kudelka A P, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma[J]. J Clin Oncol, 2000, 18(14):2733-2739.
  • 4Rose P G, Blessing J A, Ball H G, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2003, 88(2):130-135.
  • 5Berkenblit A, Tung N, Kim Y, et al. Phase I trial of docetaxel, carboplatin, and gemcitabine as first line therapy for patients with high risk epithelial tumors of mullerian origin[J]. Gynecol Oncol,2003, 89(3):486-493.
  • 6Pfisterer J, du Bois A, Wagner U, et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group[J]. Gynecol Oncol, 2004, 92(3):949-956.
  • 7Vorobiof D A, Rapoport B L, Chasen M R, et al. Phase II clinical trial of carbopaltin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy [J]. Int J Gynecol Cancer, 2003, 13(3):287-291.
  • 8Dieras V, Guastalla J P, Ferrero J M, et al. A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study[J]. Cancer Chemother Pharmacol, 2004, 53(6): 489-495.
  • 9Neijt J P, Engelholm S A, Tuxen M K, et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer[J]. J Clin Oncol, 2000, 18(17): 3084-3092.
  • 10Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomised trials Advanced Ovarian Cancer Trialists' Group[J]. Br J Cancer,1998, 78(11): 1479-1487.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部